Hikma rolls into Morocco with $158 million Promopharm buy
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals has acquired a majority stake in Promopharm, one of Morocco's leading pharmaceutical groups. Through the acquisition, Hikma will for the first time be able to enter the Moroccan market, which it estimates to be worth around $1.7 billion and set for significant growth as the government aims to expand healthcare coverage from extremely low current levels.